Abacavir Sulfate, Lamivudine, and Zidovudine Articles
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
After database review, GSK says D:A:D study "inconclusive"
18 August 2008
GSK's abacavir gets HSR warning from US FDA
4 August 2008
GSK warns of potential heart risk for HIV drug
30 June 2008
FDA starts safety review of GSK and B-MS HIV drugs
7 April 2008
CHMP requests Ziagen data to assess heart risk
7 April 2008
Drug firms want two-year delay in US state's RFID law
11 February 2008
GSK moves to help poorest fight HIV/AIDS
5 June 2006
GSK ARVs placed on EU anti-diversion list
3 May 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
Abbott, B-MS, GSK lead growing HIV Rx mkt
16 February 2004
Activists fire shot at GSK over Trizivir study
17 March 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
Funding and approving new drugs in Israel's NHI basket
18 February 2002
GlaxoSmithKline 2001 pretax exceeds forecasts
18 February 2002
Triangle to file one, drop one HIV drug
28 January 2002
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Earnings increase 41% at BioChem Pharma
1 February 2001
Stock Commentary - Europe
11 January 2001
GSK's Trizivir cleared in EU for HIV
9 January 2001
GW wins FDA approval for Trizivir
16 November 2000
GW's anti-HIV drug Trizivir backed in EU
18 July 2000
BioChem Pharma earnings up 34%
3 May 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
GW seeks backing for Trizivir, new HIV combo
20 December 1999
Showing 1-42 of 42 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
